VEGFA and neoplasm: Sorafenib targets multiple targets (Vascular endothelial growth factor, Platelet-derived growth factor receptor, and Raf), reducing tumor–stromal interactions related to carcinogenesis and metastatic capacity, and affects metabolic capacity related to tumorigenicity [41,42], whereas EBRT induces mitotic death via DNA damage as well as immunogenic stimulation [43].